REFERENCE DOCUMENT Annual Financial Report Translation for informational purposes only This Reference Document was filed with the Autorité des Marchés Financiers on April 17, 2014, pursuant to Article 212-13 of the General Regulations of the Autorité des Marchés Financiers . This Reference Document can be used in connection with an offering of securities if accompanied by a Note d’opération approved by the Autorité des Marchés Financiers. This document was prepared by the issuer and its signees are responsible for its content. CONTENTS 1. RESPONSIBLE PERSONS .......................................................................................................................................... 5 1.1. Persons responsible for information ................................................................................................................... 5 1.2. Declaration by the responsible person ................................................................................................................ 5 2. STATUTORY AUDITORS ............................................................................................................................................ 6 3. SELECTED FINANCIAL DATA................................................................................................................................. 7 4. RISK FACTORS ............................................................................................................................................................ 8 4.1. Risks specific to the Company ............................................................................................................................. 8 4.1.1. Risks related to the therapeutic approaches selected by the Company ...................................................... 8 4.1.2. Risks related to clinical trials ........................................................................................................................ 8 4.1.3. Risks related to commercial-scale production ........................................................................................... 10 4.1.4. Risks related to product adverse side effects ............................................................................................. 10 4.1.5. Risks related to the funding of the Company’s development and activities ............................................. 10 4.1.6. Risks related to previous and future losses ................................................................................................ 11 4.1.7. Specific risks related to development, manufacturing and marketing partnerships ............................... 11 4.1.8. Dependence on qualified personnel ............................................................................................................ 12 4.2. Risks related to the Company’s business segment ........................................................................................... 12 4.2.1. Risks related to competition and technological progress .......................................................................... 12 4.2.2. Specific risks related to patents and third-party intellectual property rights .......................................... 12 4.3. Financial risks .................................................................................................................................................... 13 4.3.1. Exchange rate risk ....................................................................................................................................... 13 4.3.2. Interest rate risks ........................................................................................................................................ 14 4.3.3. Liquidity risks ............................................................................................................................................. 14 4.3.4. Share risks ................................................................................................................................................... 15 4.4. Legal risks .......................................................................................................................................................... 15 4.4.1. Specific risks related to patents .................................................................................................................. 15 4.4.2. Specific risks related to patent litigation .................................................................................................... 16 4.4.3. Product liability ........................................................................................................................................... 16 4.4.4. Specific risks related to the use of hazardous products and those that are harmful to the environment ................................................................................................................................................. 17 4.5. Insurance and Risk Coverage ........................................................................................................................... 17 4.6. Regulatory risks ................................................................................................................................................. 17 4.6.1. Risks related to the Company’s regulatory environment ......................................................................... 18 4.6.2. Risks related to obtaining marketing authorizations ................................................................................ 18 4.6.3. Risks related to changes or announcements about drug reimbursement policies ................................... 19 5. INFORMATION ABOUT THE ISSUER .................................................................................................................. 20 5.1. History and development of the Company ....................................................................................................... 20 5.1.1. Legal Name and Commercial Name .......................................................................................................... 20 5.1.2. Place of Registration and Registration Number ........................................................................................ 20 5.1.3. Date of Incorporation and Duration .......................................................................................................... 20 5.1.4. Registered Office, Legal Form and Applicable Law ................................................................................. 20 5.1.5. Significant Events in the Development of the Company’s Business ......................................................... 20 5.2. Investments ........................................................................................................................................................ 22 6. BUSINESS OVERVIEW............................................................................................................................................. 23 6.1. Principal activities .............................................................................................................................................. 23 6.1.1. Nature of Business ...................................................................................................................................... 23 6.1.2. Research and Development ......................................................................................................................... 23 6.1.3. Production ................................................................................................................................................... 25 6.1.5. Other products ............................................................................................................................................ 33 6.2. Principal Markets .............................................................................................................................................. 34 6.2.1. Cancer .......................................................................................................................................................... 34 6.2.1.1. Non-small cell lung cancer .............................................................................................................. 35 6.2.1.2. Hepatic cancers ............................................................................................................................... 35 6.2.1.3. Cancers caused by the Human Papilloma Virus (HPV) ............................................................... 35 6.2.2. Chronic infectious diseases ......................................................................................................................... 36 2 6.2.2.1. Hepatitis C Virus Infection ............................................................................................................. 36 6.2.2.2. Hepatitis B Virus Infection ............................................................................................................. 37 6.2.3. Competition ................................................................................................................................................. 37 6.3. Exceptional events .............................................................................................................................................. 38 6.4. Dependence of the Company on patents, licenses and trade agreements ......................................................